Company intelligence / Profile preview

Digital Health China Technologies

Ownership: Private
Development stage: Commercial

Overview

DHC operates large-scale medical big data and artificial intelligence platforms serving over 700 tertiary hospitals in China. The company has developed national-level disease registries for oncology and rare diseases. Its AI imaging solutions have received recognition for scientific excellence. DHC’s technologies are used by thousands of customers across hospitals, public health agencies, pharmaceutical companies, insurance providers, etc. No clinical trial results as the company does not develop therapeutics.

Therapeutic areas: OncologyRare DiseasesNephrologyOther
Modalities: DeviceSoftwareAI platform
Industry: Digital Health Medical Devices

Partnerships

Huawei (jointly released Intelligent Multimodal Big Data Center System Solution)

Beyond the preview

Go deeper on Digital Health China Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Digital Health China Technologies.

Explore the full profile